HAEMATO AG: Interim report HAEMATO AG second quarter 2017

Schönefeld (pta038/31.08.2017/15:00 UTC+2) HAEMATO AG is a listed pharmaceutical company with a focus on the growth markets of patent-free and patent-protected pharmaceuticals, mainly in the high-price indicative areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In the first half of 2017, HAEMATO AG achieved sales of EUR 138,8m. An operating result of EUR 3,18m was achieved. In particular, HAEMATO AG is strategically well positioned in the specialty medicine segment. Furthermore, the current medical products currently under license will have significant future growth potential and improved margins.

The interim report published today on the reporting period from January 1, 2017 to June 30, 2017 is available for download at:
http://www.haemato.de/investoren/veroeffentlichungen/geschaeftsberichte/.

About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities is on the growth markets of patent-free and patent-protected medicines. The focus is on therapies for cancer, HIV and other chronic diseases.

(end)

Emitter:	HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld Germany
Contact Person:	Uwe Zimdars
Phone:	+49 30 8973086-70
E-Mail:	ir@haemato.de
Website:	www.haemato-ag.de
ISIN(s):	DE0006190705 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate